FrancophonIA/ELRC3.0 huggingface dataset:
English: Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
Danish: Lopper fra kæledyr infesterer ofte dyrets kurv, leje og sædvanlige hvilesteder, såsom tæpper og bløde møbler.
English: Number of tablets and strength (mg spinosad) 1 x 90 mg tablet 1 x 140 mg tablet 1 x 180 mg tablet 1 x 270 mg tablet 1 x 425 mg tablet †Cats over 8.5 kg: give the appropriate combination of tablets.
Danish: Antal tabletter og tabletstyrke (mg spinosad) 1 x 90 mg tablet 1 x 140 mg tablet 1 x 180 mg tablet 1 x 270 mg tablet 1 x 425 mg tablet †Katte over 8,5 kg: Den passende kombination af tabletter indgives.
English: Bioavailability was shown to be approximately 100%, with maximum plasma concentrations attained approximately 4-12 hours post treatment, and with half-lives of spinosyn A and spinosyn D ranging between 5 days and 20 days in cats dosed at 50-100 mg spinosad/kg bodyweight.
Danish: Halveringstiden for spinosyn A og spinosyn D var på mellem 5 dage og 20 dage hos katte doseret ved 50-100 mg spinosad/kg legemsvægt.
English: EU/2/10/115/018 (140 mg, 3 tablets) EU/2/10/115/019 (140 mg, 6 tablets) EU/2/10/115/020 (180 mg, 3 tablets) EU/2/10/115/021 (180 mg, 6 tablets) EU/2/10/115/011 (270 mg, 3 tablets) EU/2/10/115/001 (270 mg, 6 tablets) EU/2/10/115/012 (425 mg, 3 tablets) EU/2/10/115/003 (425 mg, 6 tablets) EU/2/10/115/013 (665 mg, 3 tablets) EU/2/10/115/005 (665 mg, 6 tablets) EU/2/10/115/014 (1040 mg, 3 tablets) EU/2/10/115/007 (1040 mg, 6 tablets) EU/2/10/115/015 (1620 mg, 3 tablets) EU/2/10/115/009 (1620 mg, 6 tablets)
Danish: EU/2/10/115/018 (140 mg, 3 tabletter) EU/2/10/115/019 (140 mg, 6 tabletter) EU/2/10/115/020 (180 mg, 3 tabletter) EU/2/10/115/021 (180 mg, 6 tabletter) EU/2/10/115/011 (270 mg, 3 tabletter) EU/2/10/115/001 (270 mg, 6 tabletter) EU/2/10/115/012 (425 mg, 3 tabletter) EU/2/10/115/003 (425 mg, 6 tabletter) EU/2/10/115/013 (665 mg, 3 tabletter) EU/2/10/115/005 (665 mg, 6 tabletter) EU/2/10/115/014 (1040 mg, 3 tabletter) EU/2/10/115/007 (1040 mg, 6 tabletter) EU/2/10/115/015 (1620 mg, 3 tabletter) EU/2/10/115/009 (1620 mg, 6 tabletter)
English: Also noted was diffuse hepatocellular hypertrophy in both males and females, and this finding correlated with higher pooled mean liver weights.
Danish: Desuden blev der observeret diffus hepatocellulær hypertrofi (diffust udbredt forstørrelse af levercellerne) hos både hanner og hunner, og dette fund korrelerede med en højere samlet gennemsnitlig levervægt.
English: EU/2/10/115/016 (90 mg, 3 tablets) EU/2/10/115/017 (90 mg, 6 tablets) EU/2/10/115/018 (140 mg, 3 tablets) EU/2/10/115/019 (140 mg, 6 tablets) EU/2/10/115/020 (180 mg, 3 tablets) EU/2/10/115/021 (180 mg, 6 tablets) EU/2/10/115/011 (270 mg, 3 tablets) EU/2/10/115/001 (270 mg, 6 tablets) EU/2/10/115/012 (425 mg, 3 tablets) EU/2/10/115/003 (425 mg, 6 tablets) EU/2/10/115/013 (665 mg, 3 tablets) EU/2/10/115/005 (665 mg, 6 tablets) EU/2/10/115/014 (1040 mg, 3 tablets) EU/2/10/115/007 (1040 mg, 6 tablets) EU/2/10/115/015 (1620 mg, 3 tablets) EU/2/10/115/009 (1620 mg, 6 tablets)
Danish: EU/2/10/115/016 (90 mg, 3 tabletter) EU/2/10/115/017 (90 mg, 6 tabletter) EU/2/10/115/018 (140 mg, 3 tabletter) EU/2/10/115/019 (140 mg, 6 tabletter) EU/2/10/115/020 (180 mg, 3 tabletter) EU/2/10/115/021 (180 mg, 6 tabletter) EU/2/10/115/011 (270 mg, 3 tabletter) EU/2/10/115/001 (270 mg, 6 tabletter) EU/2/10/115/012 (425 mg, 3 tabletter) EU/2/10/115/003 (425 mg, 6 tabletter) EU/2/10/115/013 (665 mg, 3 tabletter)
English: − rare (more than 1 but less than 10 animals in 10,000 animals)
Danish: Hyppigheden af bivirkninger er defineret som: - Meget almindelige (flere end 1 ud af 10 dyr viser bivirkninger i løbet af en behandling) - Almindelige (flere end 1, men færre end 10 ud af 100 dyr) - Ikke almindelige (flere end 1, men færre end 10 ud af 1.000 dyr) - Sjældne (flere end 1, men færre end 10 ud af 10.000 dyr) - Meget sjældne (færre end 1 dyr ud af 10.000 dyr, herunder isolerede rapporter).
English: Also noted were diffuse hepatocellular hypertrophy in males and females, and this finding correlated with higher pooled mean liver weights.
Danish: Desuden blev der observeret diffus hepatocellulær hypertrofi hos hanner og hunner, som korrelerede med en højere samlet gennemsnitlig levervægt.
English: In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines.
Danish: Hos katte er en almindelig set bivirkning opkastning, der forekommer i de første 48 timer efter dosering, og sandsynligvis skyldes en lokal virkning på tyndtarmen.
English: In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines.
Danish: Hos hunde er en almindeligt set bivirkning opkastning, der forekommer i de første 48 timer efter dosering og sandsynligvis skyldes en lokal virkning på tyndtarmen.
English: Pregnancy and lactation:
Danish: Brug under drægtighed og laktation:
English: To ensure maximum effectiveness, if vomiting occurs within an hour of administration and the tablet is visible, re-dose with another full dose.
Danish: Hvis der forekommer opkastning inden for en time efter indgivelse, og tabletten kan ses, skal hunden have en ny fuld dosis for at opnå maksimal effekt.
English: In cats, at doses of 75 to 100 mg/kg bodyweight per day for 5 days, given monthly for a period of six months, the most commonly observed clinical sign was vomiting.
Danish: Ved en dosis på 75 til 100 mg/legemsvægt per dag i 5 dage givet månedligt i en periode på seks måneder hos katte var opkastning det mest almindeligt sete kliniske tegn.
English: − very rare (less than 1 animal in 10,000 animals, including isolated reports).
Danish: Hyppigheden af bivirkninger er defineret som: - Meget almindelige (flere end 1 ud af 10 dyr viser bivirkninger i løbet af en behandling) - Almindelige (flere end 1, men færre end 10 ud af 100 dyr) - Ikke almindelige (flere end 1, men færre end 10 ud af 1.000 dyr) - Sjældne (flere end 1, men færre end 10 ud af 10.000 dyr) - Meget sjældne (færre end 1 ud af 10.000 dyr, herunder isolerede rapporter).
English: Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number underlined as listed below on the other:
Danish: Gyldenbrune til brune eller spættede, runde, flade tabletter med skrå kant, som er glatte på den ene side og præget med et understreget nummer, som angivet nedenfor, på den anden side:
English: As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.
Danish: Da sikkerheden deraf for diende hvalpe og killinger ikke er blevet tilstrækkeligt fastlagt, skal produktet kun anvendes til drægtige og diegivende tæver og hunkatte iht.
English: Dispose of waste material in accordance with local requirements.
Danish: Ikke anvendte veterinærlægemidler, samt affald heraf bør destrueres i henhold til lokale retningslinjer.
English: In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens.
Danish: Det antages derfor, at spinosad udskilles i kolostrum og mælk fra diegivende hunkatte.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Danish: Særlige forholdsregler der skal træffes af personer, der administrerer lægemidlet til dyr: Indtagelse ved hændeligt uheld kan forårsage bivirkninger.
English: Tan to brown, or speckled, round, flat, bevelled edge tablets, plain on one side and debossed with a number as listed below on the other:
Danish: Gyldenbrune til brune eller spættede, runde, flade tabletter med skrå kant, som er glatte på den ene side og præget med et nummer, som angivet nedenfor, på den anden side.
English: Comfortis 90 mg chewable tablets for dogs and cats Comfortis 140 mg chewable tablets for dogs and cats Comfortis 180 mg chewable tablets for dogs and cats Comfortis 270 mg chewable tablets for dogs and cats Comfortis 425 mg chewable tablets for dogs and cats Comfortis 665 mg chewable tablets for dogs
Danish: Comfortis 90 mg tyggetabletter til hunde og katte Comfortis 140 mg tyggetabletter til hunde og katte Comfortis 180 mg tyggetabletter til hunde og katte Comfortis 270 mg tyggetabletter til hunde og katte Comfortis 425 mg tyggetabletter til hunde og katte Comfortis 665 mg tyggetabletter til hunde
English: Comfortis 90 mg chewable tablets for dogs and cats Comfortis 140 mg chewable tablets for dogs and cats Comfortis 180 mg chewable tablets for dogs and cats Comfortis 270 mg chewable tablets for dogs and cats Comfortis 425 mg chewable tablets for dogs and cats Comfortis 665 mg chewable tablets for dogs Comfortis 1040 mg chewable tablets for dogs Comfortis 1620 mg chewable tablets for dogs
Danish: Comfortis 90 mg tyggetabletter til hunde og katte Comfortis 140 mg tyggetabletter til hunde og katte Comfortis 180 mg tyggetabletter til hunde og katte Comfortis 270 mg tyggetabletter til hunde og katte Comfortis 425 mg tyggetabletter til hunde og katte Comfortis 665 mg tyggetabletter til hunde Comfortis 1040 mg tyggetabletter til hunde Comfortis 1620 mg tyggetabletter til hunde
English: PACKAGE LEAFLET FOR Comfortis 90 mg chewable tablets for dogs and cats Comfortis 140 mg chewable tablets for dogs and cats Comfortis 180 mg chewable tablets for dogs and cats Comfortis 270 mg chewable tablets for dogs and cats Comfortis 425 mg chewable tablets for dogs and cats Comfortis 665 mg chewable tablets for dogs Comfortis 1040 mg chewable tablets for dogs Comfortis 1620 mg chewable tablets for dogs
Danish: INDLÆGSSEDDEL TIL: Comfortis 90 mg tyggetabletter til hunde og katte Comfortis 140 mg tyggetabletter til hunde og katte Comfortis 180 mg tyggetabletter til hunde og katte Comfortis 270 mg tyggetabletter til hunde og katte Comfortis 425 mg tyggetabletter til hunde og katte Comfortis 665 mg tyggetabletter til hunde Comfortis 1040 mg tyggetabletter til hunde Comfortis 1620 mg tyggetabletter til hunde
English: Regarding safety, in overall it was considered acceptable.
Danish: Sikkerheden blev overordnet anset for at være acceptabel.
English: This effect was also maintained in the long-term.
Danish: Denne virkning holdt sig også på lang sigt.
English: Another study showed maintenance of this effect for 24 months.
Danish: En anden undersøgelse viste, at denne virkning holdt sig i 24 måneder.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xadago on 24 February 2015.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Xadago den 24. februar 2015.
English: Treatment should be started at a dose of 50 mg a day and the doctor may increase the dose up to 100 mg a day based on patient's need.
Danish: Behandlingen bør påbegyndes med en dosis på 50 mg dagligt, og lægen kan sætte dosis op til 100 mg dagligt afhængigt af patientens behov.
English: The full EPAR and risk management plan summary for Xadago can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR og resuméet af risikostyringsplanen for Xadago findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Xadago.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Xadago.
English: Xadago is available as tablets (50 and 100 mg) and can only be obtained with a prescription.
Danish: Xadago leveres som tabletter (50 og 100 mg) og udleveres kun på recept.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Xadago's benefits are greater than its risks and recommended that it be approved for use in the EU.
Danish: Agenturets Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at fordelene ved Xadago overstiger risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: A risk management plan has been developed to ensure that Xadago is used as safely as possible.
Danish: Der er udarbejdet en risikostyringsplan for at sikre, at Xadago anvendes så sikkert som muligt.
English: Xadago contains the active substance safinamide.
Danish: Xadago indeholder det aktive stof safinamid.
English: Other information about Xadago
Danish: Andre oplysninger om Xadago
English: Xadago safinamide
Danish: Xadago safinamid
English: It blocks the enzyme monoamine oxidase type B (which breaks down dopamine), thereby helping to restore dopamine levels in the brain and improving the patient's symptoms.
Danish: Det blokerer enzymet monoaminoxidase type B (som nedbryder dopamin) og medvirker derved til at genoprette hjernens indhold af dopamin, så patientens symptomer bedres.
English: What is Xadago and what is it used for?
Danish: Hvad er Xadago, og hvad anvendes det til?
English: The most common side effects with Xadago (which may affect up to 1 in 10 people) are insomnia (difficulty sleeping), dyskinesia (difficulty controlling movement), somnolence (sleepiness), dizziness, headache, worsening of existing Parkinson's disease, cataract (clouding of the lens), orthostatic hypotension (drop in blood pressure when standing up), nausea (feeling sick) and falls.
Danish: De hyppigste bivirkninger ved Xadago (som kan forekomme hos op til 1 ud af hver 10 personer) er søvnløshed, vanskelighed ved at kontrollere bevægelserne (dyskinesi), søvnighed (somnolens), svimmelhed, hovedpine, forværring af eksisterende Parkinsons sygdom, grå stær (katarakt), blodtryksfald ved overgang til stående stilling (ortostatisk hypotension), kvalme og faldtendens.
English: What measures are being taken to ensure the safe and effective use of Xadago?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Xadago?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xadago, including the appropriate precautions to be followed by healthcare professionals and patients.
Danish: På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Xadago, herunder passende forholdsregler, som sundhedspersonale og patienter skal følge.
English: Why is Xadago approved?
Danish: Hvorfor blev Xadago godkendt?
English: The active substance in Xadago, safinamide, is a ‘monoamine oxidase-B (MAO-B) inhibitor'.
Danish: Det aktive stof i Xadago, safinamid, er en monoaminoxidase B-hæmmer (MAO-B-hæmmer).
English: Xadago is a medicine used to treat Parkinson's disease, a progressive brain disorder that causes shaking, slow movement and muscular stiffness.
Danish: Xadago er et lægemiddel til behandling af Parkinsons sygdom, der er en fremadskridende hjernesygdom, som medfører rysten, langsomme bevægelser og muskelstivhed.
English: Xadago must not be used in patients with severe liver problems, in patients treated with pethidine or other MAO inhibiting medicines, or in patients with certain conditions affecting the eyes.
Danish: Xadago må ikke anvendes hos patienter med svære leverproblemer, patienter i behandling med petidin, patienter i behandling med andre MAO-hæmmere eller patienter med visse øjensygdomme.
English: The Committee concluded that the effect of Xadago on the daily time that patients lived without motor symptoms was of clinical relevance, also taking into account the response reported in the literature for other Parkinson's medicines.
Danish: Udvalget konkluderede, at virkningen af Xadago på det daglige tidsrum, hvor patienterne var uden bevægelsessymptomer, havde klinisk betydning, også sammenholdt med beskrivelser i litteraturen af virkningen af andre lægemidler mod Parkinsons sygdom.
English: It is not intended to provide practical advice on how to use Xadago.
Danish: Det er ikke en praktisk vejledning i, hvordan Xadago bør anvendes.
English: For more information about treatment with Xadago, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Xadago, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: What are the risks associated with Xadago?
Danish: Hvilke risici er der forbundet med Xadago?
English: In both studies, 6 months treatment with Xadago increased the time during the day during which patients were ‘on' and able to move by 30-60 minutes when compared with placebo.
Danish: Begge undersøgelser viste, at det daglige tidsrum, hvor patienterne var “on” og kunne bevæge sig, efter 6 måneders behandling med Xadago var forlænget med 30-60 minutter i forhold til placebo.
English: For the full list of all side effects reported with Xadago, see the package leaflet.
Danish: Den fuldstændige liste over indberettede bivirkninger ved Xadago fremgår af indlægssedlen.
English: For practical information about using Xadago, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Xadago, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: How is Xadago used?
Danish: Hvordan anvendes Xadago?
English: These fluctuations occur when the effect of levodopa wears off and the patient suddenly switches from being ‘on' and able to move about to being ‘off' and having difficulty moving about.
Danish: Dette medfører pludselige skift mellem “on-perioder”, hvor patienten er i stand til at bevæge sig, og “off-perioder”, hvor patienten har vanskeligt ved at bevæge sig.
English: It is used in addition to levodopa (a medicine commonly used to treat the symptoms of Parkinson's disease) either alone or in combination with other medicines for Parkinson's, in patients with mid- to late-stage Parkinson's disease who are having ‘motor fluctuations'.
Danish: Hos disse patienter anvendes det i kombination med levodopa, der er et almindeligt anvendt lægemiddel til behandling af symptomerne på Parkinsons sygdom, enten alene eller yderligere kombineret med andre lægemidler mod Parkinsons.
English: What benefits of Xadago have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Xadago?
English: In patients with Parkinson's disease, certain cells in the brain that produce dopamine die, and as dopamine is involved in controlling movement, the patient's movement worsens over time.
Danish: Hos patienter med Parkinsons sygdom dør visse hjerneceller, der producerer dopamin.
English: Xadago was also investigated as an add-on to treatment in 2 studies in patients with early Parkinson's disease without fluctuations, but these studies did not show a clear benefit and the company did not pursue this use as part of the application.
Danish: Xadago blev desuden anvendt som tillægsbehandling i to undersøgelser ved Parkinsons sygdom i tidligt stadium uden fluktuationer.
English: How does Xadago work?
Danish: Hvordan virker Xadago?
English: Xadago, as an add-on treatment to levodopa with or without other medicines for Parkinson's disease, has been compared with placebo (a dummy treatment) in two main studies involving 1,218 patients with late stage Parkinson's disease who experienced fluctuations.
Danish: Der er udført to hovedundersøgelser med Xadago hos 1 218 patienter med Parkinsons sygdom i sent stadium med fluktuationer.
English: Do not take two doses at the same time.
Danish: De må ikke tage to doseringer på samme tid
English: Speak to your doctor first.
Danish: Tal først med lægen.
English: This makes it difficult to pass urine.
Danish: Det gør det svært for urinen at passere.
English: This should be considered when interpreting laboratory data.
Danish: Det skal der tages hensyn til ved fortolkning af laboratoriedata.
English: Trough levels at 24 hours are, however, similar.
Danish: Bundniveauet efter 24 timer er imidlertid det samme.
English: The label on the carton will tell you how many tablets you should take and when.
Danish: Etiketten på kartonen angiver, hvor mange tabletter De skal tage og hvornår.
English: • Other medicines used in the treatment of high blood pressure
Danish: • Anden medicin, som bruges i behandling af højt blodtryk
English: The majority of the adverse reactions were transient.
Danish: Størstedelen af bivirkningerne var forbigående.
English: Close control of blood pressure.
Danish: Tæt kontrol af blodtryk.
English: Adults and the elderly:
Danish: Voksne og ældre:
English: Symptomatic treatment.
Danish: Symptomatisk behandling.
English: Be especially careful when you take you first start taking the tablets.
Danish: De bør især være forsigtig, når De tager tabletterne første gang.
English: The usual dose is one tablet each day.
Danish: Den normale dosering er en tablet dagligt.
English: In hypertensive patients both conditions are treated concomitantly.
Danish: I hypertensive patienter behandles begge sygdomme samtidigt.
English: You should lie down on your back with your feet higher than your head.
Danish: Hvis det sker, skal De lægge Dem på ryggen og sørge for at holde fødderne højere end hovedet.
English: Cellulose, microcrystalline Povidone K 29-32
Danish: Cellulose, mikrokrystallisk Povidon K 29-32
English: PVC/PVDC/aluminium blister.
Danish: PVC/PVDC/aluminiumblister.
English: even if their symptoms are the same as yours.
Danish: Det kunne skade dem, selv om deres symptomer er de samme som Deres egne.
English: Your doctor may increase your dose to the maximum recommended dose of two tablets each day.
Danish: Deres læge kan øge doseringen til det anbefalede maksimum på to tabletter dagligt.
English: Do not crush or chew the tablets.
Danish: Lad være med at knuse eller tygge tabletterne.
English: Frequencies are defined as very common (≥1/10); common (>1/100 to <1/10); uncommon (>1/1000 to <1/100); rare (>1/10 000 to <1/1000); very rare (<1/10
Danish: Frekvenserne defineres som meget almindelige (≥1/10); almindelig (>1/100 til <1/10); usædvanlig (>1/1000 til <1/100); sjældne (>1/10 000 til <1/1000); meget sjældne (<1/10 000).
English: Possibly hypoglycaemia, hypokalaemia.
Danish: Eventuel hypoglykæmi, hypokalæmi.
English: However, if you miss a dose, just take it as soon as you remember.
Danish: Hvis De glemmer at tage en dosering, skal De blot tage den, så snart De kommer i tanke om det.
English: A dosage regime of 82 mg/kg/day (8 times the human exposure) was associated with reduced foetal survival.
Danish: Et doseringsregimen på 82 mg/kg/dag (8 gange den humane eksponering) var forbundet med reduceret fosteroverlevelse.
English: The occurrence of adverse reactions are mainly due to the pharmacological properties of the medicinal product.
Danish: Forekomsten af bivirkninger skyldes navnlig lægemidlets farmakologiske egenskaber.
English: This helps to lower raised blood pressure.
Danish: Det hjælper med til at sænke et forhøjet blodtryk.
English: Very rare: increase of serum creatinine.
Danish: Meget sjælden: forhøjet serum kreatinin.
English: They are available in PVC/PVDC/aluminium blisters packs of 28 tablets [20, 30, 50, 98, 100 and 500 tablets].
Danish: De leveres i PVC/PVDC/aluminium-blisterpakninger med 28 tabletter [20, 30, 50, 98, 100 og 500 tabletter].
English: Butylhydroxytoluene (E321) α-Tocopherol
Danish: Butylhydroxytoluen (E321) α-tocopherol
English: The prolonged-release tablets should not be chewed, divided or crushed.
Danish: Depottabletterne må ikke tygges, deles eller knuses.
English: This medicinal product does not require any special storage conditions.
Danish: Dette lægemiddel kræver ingen særlige forholdsregler for opbevaringen.
English: Ratiopharm Hungaria Kft. Uzoki utca 36/a 1145 Budapest, Hungary Tel: 0036 1 2732730
Danish: Ratiopharm Hungaria Kft. Uzoki utca 36/a 1145 Budapest, Ungarn Tlf.: 0036 1 2732730